VivoSeq
Ophthalmology

Meibomian Gland Dysfunction

0

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Meibomian Gland Dysfunction is an early-stage landscape with 0 programs across 3 companies. The most active players are Cloudbreak Therapeutics, LLC, Tarsus Pharmaceuticals, Inc., AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cloudbreak Therapeutics, LLC

0 programs

PreclinicalT

Tarsus Pharmaceuticals, Inc.

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed17 · 74%
Unknown status3 · 13%
Not yet recruiting1 · 4%
Recruiting1 · 4%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction
Recruiting·LLaboratorios Thea, Spain·Phase 4·NCT05159284·54 enrolled
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
Active, not recruiting·TTarsus Pharmaceuticals, Inc.·Phase 2·NCT06054217·36 enrolled
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
Not yet recruiting·UUniversity of Alabama at Birmingham·Phase 4·NCT07224529·48 enrolled
Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction
Completed·HHovione Scientia Limited·Phase 2·NCT03888378·270 enrolled
Treatment Regimens in Meibomian Gland Dysfunction
Completed·TTauber Eye Center·Phase 4·NCT05594745·60 enrolled
Comparison Between Continuous and Pulsed Oral Doxycycline Treatment Protocols for Refractory Meibomian Gland Dysfunction
Completed·UUniversity of Milan·N/A·NCT06520007·65 enrolled
Therapeutic Effectiveness of Different Machines in Intense Pulsed Light Treatment of Meibomian Gland Dysfunction
Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06034626·216 enrolled
Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)
Completed·—·Phase 2/3·NCT04314362·32 enrolled
Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction
Completed·PPeking University Third Hospital·N/A·NCT02958514·20 enrolled
Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction
Completed·MMahidol University·Phase 4·NCT00705510·70 enrolled
Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction
Completed·MMedical University of Vienna·Phase 4·NCT03162497·23 enrolled
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
Completed·—·Phase 2·NCT04391959·31 enrolled
Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
Completed·OORA, Inc.·Phase 2·NCT00755183·60 enrolled
Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction
Completed·YYonsei University·N/A·NCT02618304·45 enrolled
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Completed·CCloudbreak Therapeutics, LLC·Phase 2·NCT05261386·95 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)